Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents-Reference-Cited by-同舟云学术

Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents

Published:2012 Issue:5 Volume:98 Page:443-450
ISSN:0006-3525
Container-title:Biopolymers
language:en
Short-container-title:Biopolymers

Author:

Day Jonathan W.,Gelfanov Vasily,Smiley David,Carrington Paul E.,Eiermann George,Chicchi Gary,Erion Mark D.,Gidda Jas,Thornberry Nancy A.,Tschöp Matthias H.,Marsh Donald J.,SinhaRoy Ranabir,DiMarchi Richard,Pocai Alessandro

Publisher

Wiley

Subject

Organic Chemistry,Biomaterials,Biochemistry,General Medicine,Biophysics

Reference18 articles.

1. Gut hormones as pharmaceuticals

2. Intestinal Hormones and Regulation of Satiety: The Case for CCK, GLP-1, PYY, and Apo A-IV

3. Obesity treatment: novel peripheral targets

4. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes

5. Glucagon and regulation of glucose metabolism

Cited by 117 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transforming obesity: The advancement of multi-receptor drugs;Cell;2024-07

2. Evaluating glucose-dependent insulinotropic polypeptide and glucagon as key regulators of insulin secretion in the pancreatic islet;American Journal of Physiology-Endocrinology and Metabolism;2024-07-01

3. Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity;Biomedicine & Pharmacotherapy;2024-07

4. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study;Journal of Hepatology;2024-07

5. Incretin and glucagon receptor polypharmacology in chronic kidney disease;American Journal of Physiology-Endocrinology and Metabolism;2024-06-01